Comparison of Direct and Indirect Solid-Phase Microradioimmunoassays for the Detection of Viral Antigens and Antiviral Antibody

JOEL D. ROSENTHAL, KOZABURO HAYASHI, AND ABNER L. NOTKINS

Laboratory of Microbiology and Immunology, National Institute of Dental Research, Bethesda, Maryland 20014

Received for publication 22 December 1972

Viral antigens were fixed to the surface of microtiter wells, and serial dilutions of antiviral antibody were added. The amount of antiviral antibody bound to viral antigens was determined by measuring the extent to which the antiviral antibody either inhibited the specific binding of $^{125}$I-labeled antiviral immunoglobulin G (IgG) (direct technique) or enhanced the specific binding of $^{125}$I-labeled anti-IgG (indirect technique). Immune complexes composed of viral antigens and antiviral antibody (human) could be detected by the binding of $^{125}$I-labeled rheumatoid factor. Specific binding was influenced by the concentration of protein in the diluents used during the different steps of the procedure. A high concentration of protein in the diluent used with the viral antigens decreased specific binding, whereas a high concentration of protein in the diluent used with $^{125}$I-labeled anti-IgG increased specific binding by decreasing nonspecific attachment of the labeled anti-IgG. Under the conditions employed, the titer of a given antiviral serum was several hundredfold greater by the indirect than by the direct technique.

Radioimmunoassays (RIA) have been widely used in the study of a variety of biological problems (20). However, the application of these techniques to experimental and diagnostic viral serology has been slow. Radioimmuno-precipitation (RIP) procedures have received the most attention (1, 4, 6, 7, 9, 12, 13, 17, 21, 24, 25, 28, 29). Generally, labeled virus is incubated with dilutions of antiviral antibody and precipitated with anti-immunoglobulin. The titer of antiviral antibody is determined by measuring the amount of radiolabeled virus that has been precipitated. Recently, solid-phase assays, based on either the attachment of radiolabeled antibody to viral antigens or the inhibition of attachment of radiolabeled virus to antibody-coated tubes (5, 10, 11, 15, 17, 22, 26; K. Hayashi, D. Lodmell, J. Rosenthal, and A. L. Notkins, J. Immunol., in press; J. Rosenthal, K. Hayashi, and A. L. Notkins, J. Gen. Virol., in press) have been used to detect viral antigens and measure antiviral antibody. The potential advantages of solid-phase over RIP assays and the use of radiolabeled antibody over radiolabeled virus are the greater speed in processing large numbers of samples and the greater availability and ease in labeling antibody. Solid-phase assays also can be miniaturized, and recently we described a technically simple and rapid indirect solid-phase micro-RIA for measuring antiviral antibody based on the attachment of $^{125}$I-labeled anti-immunoglobulin to antiviral antibody (26). In the present report we enumerate some of the factors which affect the sensitivity of this indirect technique, describe a direct inhibition assay which employs $^{125}$I-labeled antiviral IgG, and show how the indirect technique can be used to measure viral antigens.

MATERIALS AND METHODS

Tissue culture. Primary rabbit kidney cells (PRK) were prepared and maintained as previously described (14). Growth medium consisted of Eagle minimal essential medium with 0.5% lactalbumin hydrolysate, 10% heat-inactivated calf serum, and antibiotics (100 U of penicillin per ml, 50 μg of neomycin per ml, 100 U of mycostatin per ml, and 100 U of streptomycin per ml).

Preparation of viral and control antigens. Monolayers of PRK cells were infected with herpes simplex virus (HSV) (type 1) or vaccinia virus (strain CVI-79) (19) at a virus-to-cell ratio of 10. Uninfected
monolayers served as controls. Approximately 20 h after infection, the medium was removed and the cells were lysed by freezing and thawing three times. The lysate from approximately 2 × 10⁶ infected or uninfected cells was resuspended in 20 ml of phosphate-buffered saline (PBS) containing calcium and magnesium, sonicated (15 s), and centrifuged at 1,400 × g for 15 min. Supernatant fluids served as the source of viral or control antigens. Viral titers were determined by plaque assay on PRK cells (14). Semipurified HSV was prepared by differential and rate zonal centrifugation. Stock virus was clarified and then centrifuged in an SW30 rotor at 78,000 × g for 120 min. The pellet was resuspended in PBS and centrifuged in an SW41 rotor at 100,000 × g for 120 min through a 10 to 40% (wt/wt) linear sucrose gradient onto a cesium chloride cushion (1.8 g/ml). The appropriate fractions were pooled, dialyzed, and diluted 1:5 in PBS before use.

Antisera. Hyperimmune sera to HSV and vaccinia virus were prepared in rabbits, and the 50% plaque neutralization titers were approximately 1:2,000 (3). Normal rabbit serum was obtained from unimmunized rabbits. Immune serum globulin obtained from Cutter Laboratories, Berkeley, Calif., served as the source of human antibody against HSV. Unless indicated otherwise, rabbit anti-HSV serum was used in all experiments. Antiserum to rabbit immunoglobulin G (IgG) was prepared by hyperimmunizing goats with the purified IgG in Freund complete adjuvant. The IgG fractions of the various sera were prepared by ammonium sulfate precipitation and Sephadex G-200 chromatography (14). Rheumatoid factor (RF) was prepared from human serum by the method of Schrohenloher et al. (27), and the titer, as measured by agglutination of Latex particles coated with human globulins, was 1,280. Immunoglobulins were labeled with ¹²⁵I by the chloramine-T method (18, 23).

1. ADD VIRAL AND CONTROL ANTIGENS, DRY, FIX
2. ADD SERIAL DILUTIONS OF ANTIVIRAL ANTIBODY (Incubate 1 hour/37°C)
3. WASH × 10
4. FLICK OUT EXCESS WATER
5. ADD ¹²⁵I-LABELED ANTI-IMMUNOGLOBULIN (Incubate 1 hour/37°C)
6. ASPIRATE, WASH × 10, FLICK OUT EXCESS WATER
7. CUT, DROP WELLS INTO VIALS
8. COUNT WITH AUTO-GAMMA SPECTROMETER, TABULATE AND/OR SEND DATA TO COMPUTER

Fig. 1. Schematic diagram of solid-phase indirect microradioimmunooassay.
dividing the average counts per minute bound to wells containing viral antigens by the counts per minute bound to wells containing control antigens. The reciprocal of the highest serum dilution that resulted in a binding ratio equal to or greater than 1.5 was taken as the end point of the antiviral activity (26). All data are expressed as the average of duplicate reactions.

RESULTS

Detection of antiviral antibody by direct technique. The ability of 125I-labeled antiviral IgG to bind specifically to viral antigens adherent to the surface of polyvinyl wells is shown in Table 1. Nearly 10 times as much 125I-labeled anti-HSV IgG bound to wells containing HSV antigens than to wells containing vaccinia or control antigens. Similarly, more 125I-labeled anti-vaccinia IgG bound to vaccinia than to HSV or control antigens.

Detection of antiviral antibody by inhibition of direct technique. The ability of unlabeled antiviral antibody to block the binding of 125I-labeled anti-HSV IgG is illustrated in Fig. 2. Serial twofold dilutions of unlabeled anti-HSV serum were added to wells containing HSV or control antigens and then 125I-labeled anti-HSV IgG was added. It can be seen that a 1:10 dilution of unlabeled anti-HSV serum inhibited the binding of labeled anti-HSV IgG by nearly 90%. Fifty percent inhibition was produced by a 1:40 dilution of unlabeled antiviral serum.

Detection of antiviral antibody by indirect technique. A comparison of the indirect micro-RIA (Table 2) with the direct inhibition technique (Fig. 2) shows that the former is far more sensitive. Whereas the titer of anti-HSV antibody by the direct inhibition technique was 40, the titer of the same serum by the indirect technique was 16,000. The data in Table 2 also show that, when 125I-labeled RF was substituted for 125I-labeled anti-IgG, specific binding did not occur.

**Table 1. Specificity of binding of 125I-labeled antiviral antibody**

| Antigens | 125I-labeled anti-HSV IgG (counts/min) | 125I-labeled anti-vaccinia IgG (counts/min) |
|----------|----------------------------------------|------------------------------------------|
| HSV      | 3,720                                  | 1,189                                    |
| Vaccinia | 367                                    | 2,962                                    |
| Control  | 378                                    | 945                                      |

* Wells containing HSV, vaccinia, or control antigens were incubated for 1 h at 37°C with 125I-labeled antiviral IgG (diluted 1:10 in growth medium). The wells then were washed and counted for radioactivity.

**Fig. 2. Inhibition of binding of 125I-labeled anti-HSV IgG by unlabeled anti-HSV serum.** Serial twofold dilutions of unlabeled anti-HSV serum were added to wells containing HSV or control antigens. After 1 h at 37°C the serum was removed, and 125I-labeled anti-HSV IgG (diluted 1:8 in growth medium) was added. At the end of 1 h the wells were washed, and the inhibition of binding produced by the unlabeled serum was determined.

**Table 2. Titer of antiviral antibody as measured by the binding of 125I-labeled goat anti-rabbit IgG or 125I-labeled rheumatoid factor (RF)**

| Viral antigens | Antiviral serum | 125I-labeled immuno-globulin | Titer of antiviral serum* |
|----------------|-----------------|------------------------------|--------------------------|
| HSV            | Anti-HSV (rabbit) | Anti-IgG                      | 16,000                   |
| HSV            | Anti-HSV (rabbit) | RF                           | 256                      |
| HSV            | Anti-HSV (human) | RF                           | 512                      |
| Vaccinia       | Anti-vaccinia (rabbit) | Anti-IgG                  | 4,000                    |
| Vaccinia       | Anti-vaccinia (rabbit) | RF                     | 256                      |

*Microtiter wells containing HSV, vaccinia, or control antigens were incubated for 1 h with serial twofold dilutions of each of the above antiviral sera, washed, and incubated for 1 additional h with 125I-labeled anti-IgG or 125I-labeled RF. The wells then were washed and counted for radioactivity.

* Titer represents the reciprocal of the highest serum dilution that resulted in a binding ratio equal to or greater than 1.5.
occur, but the detection of antiviral antibody by RF was considerably less sensitive. RF also bound to immune complexes composed of HSV and anti-HSV antibody of human origin.

**Factors influencing specific binding of radiolabeled immunoglobulins.** During the course of these experiments it became apparent that a number of factors could influence the sensitivity of both the direct and indirect RIA. Nonspecific attachment of $^{125}$I-labeled immunoglobulins to polyvinyl wells resulted in a high background of radioactivity and a marked reduction in the apparent binding ratio. This could be largely prevented, however, by adding protein to the appropriate diluent. Wells containing semipurified HSV antigens were treated for 1 h at 37 C with PBS, 1% bovine serum albumin (BSA), or 1% calf serum and then incubated with $^{125}$I-labeled anti-IgG diluted in PBS. Table 3 shows that wells which had been pretreated with 1% protein bound approximately one-half the amount of $^{125}$I-labeled anti-IgG as wells pretreated with PBS. However, if the $^{125}$I-labeled anti-IgG was diluted in 1% BSA or 1% calf serum instead of PBS, nonspecific attachment was reduced by up to 95%.

The effect of nonspecific on the binding ratio of $^{125}$I-labeled anti-IgG is demonstrated in Table 4. It can be seen that the binding ratio increased from 1.4 when PBS was used as the diluent to 7.5 when 10% growth medium was used as the diluent. The increase in the binding ratio was associated with a corresponding decrease in the nonspecific attachment of $^{125}$I-labeled anti-IgG.

In contrast to the increase in the binding ratio which occurred when increasing concentrations of serum were used in the diluent for $^{125}$I-labeled anti-IgG, a decrease in the binding ratio occurred when increasing concentrations of serum were used in the diluent for viral and control antigens during the initial fixation of these antigens to polyvinyl wells. Antigens were diluted in PBS containing various concentrations of BSA and then fixed to microtiter wells in the usual way. The binding of antiviral antibody was measured by indirect RIA. The data in Table 5 show that high concentrations of BSA markedly decreased the subsequent binding of $^{125}$I-labeled anti-IgG and reduced the binding ratio from 11.3 to 1.9.

**Table 4. Effect on nonspecific attachment of $^{125}$I-labeled anti-IgG on the binding ratio**

| Diluent for $^{125}$I-labeled anti-IgG | Anti-HSV antibody (counts/min) | Normal serum (counts/min) | Binding ratio |
|--------------------------------------|-------------------------------|---------------------------|--------------|
| PBS                                  | 3,920                         | 2,714                     | 1.4          |
| 0.25% BSA                            | 1,047                         | 472                       | 2.2          |
| 2.0% BSA                             | 1,032                         | 402                       | 2.6          |
| 1.0% BSA                             | 1,115                         | 356                       | 3.1          |
| 10% Calf serum                       | 777                           | 126                       | 6.1          |
| 10% Growth medium                    | 668                           | 89                        | 7.5          |

*Anti-HSV antibody or normal rabbit serum, diluted 1:100 in 1% BSA, was added to wells containing semipurified HSV antigens. At the end of 1 h the wells were washed and incubated for 1 additional h with $^{125}$I-labeled anti-IgG which had been diluted 1:80 in each of the above diluents. The wells were then washed and counted for radioactivity.

**Table 5. Effect of reagents used to dilute viral and control antibodies on the binding of antiviral antibody**

| Reagents used to dilute antigens | Viral antigens (counts/min) | Control antigens (counts/min) | Binding ratio |
|---------------------------------|-----------------------------|-------------------------------|--------------|
| PBS                             | 1,774                       | 156                          | 11.3         |
| 0.03% BSA                       | 1,464                       | 146                          | 10.0         |
| 0.06% BSA                       | 1,301                       | 122                          | 10.6         |
| 0.125% BSA                      | 939                         | 96                           | 9.7          |
| 0.25% BSA                       | 612                         | 90                           | 6.8          |
| 0.5% BSA                        | 294                         | 86                           | 3.4          |
| 1.0% BSA                        | 128                         | 70                           | 1.8          |
| 10.0% Calf serum                | 125                         | 64                           | 2.0          |
| Growth medium                   | 110                         | 58                           | 1.9          |

*Vaccinia and control antigens were diluted 1:9 with each of the above reagents and then fixed to microtiter wells in the usual way. Anti-vaccinia antibody (diluted 1:200 in growth medium) was added. At the end of 1 h the wells were washed, incubated for 1 additional h with $^{125}$I-labeled anti-IgG (diluted 1:80 in growth medium), washed again, and counted for radioactivity.
Measurement of viral antigens by indirect technique. Preparations containing viral or control antigens were diluted serially in PBS, fixed to microtiter wells, and quantitated by the indirect RIA. Fig. 3 shows that, at the lower dilutions of antigen, considerably more radioactivity bound to wells containing viral than control antigens. Marked differences still could be detected at a 1:128 dilution of the viral antigens.

DISCUSSION

Previously we showed that 125I-labeled antiviral antibody could be used to detect viral antigens on the surface of infected cells (15; Hayashi, Lodmell, Rosenthal, and Notkins, J. Immunol., in press; Rosenthal, Hayashi, and Notkins, J. Gen. Virol., in press) and that viral antigens extracted from infected cells adhered to the surface of polyvinyl wells (26). The present experiments show that 125I-labeled antiviral antibody will bind to the adherent antigens (Fig. 4A). Although the amount of 125I-labeled antibody which binds to the viral antigens could be used to measure the titer of the antiviral antibody, this technique is not practical for screening a large number of samples because each serum would have to be individually labeled. The inhibition of binding of 125I-labeled antiviral antibody by unlabeled antiviral antibody (Fig. 4B) avoids this difficulty, but, at least under the conditions employed here, the sensitivity is low. In contrast, the indirect technique is very sensitive and has the advantage of using one labeled reagent for detecting antibody to a variety of viruses. Presumably, the greater sensitivity of the indirect technique is due to the amplification resulting from the attachment of more than one molecule of 125I-labeled anti-immunoglobulin to each molecule of unlabeled antiviral antibody (Fig. 4C).

A number of factors can affect the sensitivity of these assays. First, nonspecific binding of 125I-labeled anti-immunoglobulin to polyvinyl wells can obscure specific differences in binding. Nonspecific binding, however, can be reduced by adding BSA to the labeled anti-immunoglobulin. The BSA apparently competes with the labeled immunoglobulin for nonspecific binding sites on the surface of the polyvinyl wells. In our experiments, the addition of BSA to the 125I-labeled immunoglobulin was markedly more effective in preventing nonspecific binding than pretreatment of the wells with BSA or calf serum (Tables 3 and 4). This might be due to the loss of protein "coat" from the surface of the wells as a result of repeated washings.

The conditions under which the viral antigens are allowed to adhere to the surface of the polyvinyl wells also are important. The highest binding ratio was obtained when the antigens were diluted in medium free of protein. When the antigens were diluted in medium containing protein, the binding ratio was greatly reduced. Whether the protein competes with the viral antigens for sites on the surface of the wells or whether the protein covers the viral antigens and makes them inaccessible to antibody is not certain. There also is some evidence that, if the viral antigens are fixed in the presence of a high concentration of protein, the antigens are more readily washed off the plate (unpublished observations). Thus, the highest binding ratio is obtained when the diluent for the antigen contains little protein, while the diluent for the labeled anti-immunoglobulin contains high protein.

RF, which is capable of binding to immune
complexes on the surface of virus-infected cells
(Hayashi, Lodmell, Rosenthal, and Notkins, J.
Immunol., in press) and to infectious virus-
antibody complexes (2), also is capable of
reacting with immune complexes in the solid-
phase micro-RIA. The titer of antiviral anti-
body as measured by this technique was con-
siderably lower than that obtained with ^125^I-
labeled anti-immunoglobulin. It should be
emphasized, however, that the anti-immuno-
globulin was prepared by hyperimmunization
and presumably has a greater affinity for
immunoglobulins than RF has for immune
complexes. In theory, at least, one possible
advantage of RF over anti-immunoglobulin is
that the former reacts with immune complexes,
but not native immunoglobulin. Thus, ^125^I-
labeled RF might prove useful in the detection
of immune complexes. The ability of RF to
bind to immune complexes, however, points to
potential problems that might arise with the
indirect micro-RIA technique. Since RF is
found in about 1% of the population (16),
serum containing antiviral antibody also might
contain RF. Thus, RF might bind to antiviral
antibody once the latter forms a complex with
viral antigens. This might interfere with the
subsequent attachment of ^125^I-labeled anti-
immunoglobulin. Whether this will prove to be
a real problem or whether the concentration of
RF in most sera is so low that it will be
diluted out before the end point of the antiviral
antibody is reached remains to be established.

The indirect technique also might be used to
determine the class of the antiviral immuno-
globulin bound to the viral antigens by employ-
ing specific anti-immunoglobulins (e.g., anti-
IgG, anti-IgM, anti-IgA) (8, 11). In fact, to
avoid false negatives in detecting and titrating
antiviral antibody, the routine preparation of
^125^I-labeled anti-immunoglobulin probably
should contain antibodies against the several
different immunoglobulin classes.

In conclusion, solid-phase micro-RIA proce-
dures seem to have a number of advantages
over many of the commonly used serological
techniques and with modifications and refine-
ments should find broad application in viral
serology. In each case, optimal conditions for
the adherence of viral antigens to the micro-
titer wells must be carefully worked out, and
nonspecific binding of radiolabeled immuno-
globulin must be prevented. Greater specificity
and sensitivity will be achieved, undoubtedly,
by employing highly purified viral antigens and
highly specific radiolabeled immunoglobulins.
LITERATURE CITED

1. Aach, R. D., J. W. Grisham, and C. W. Parker. 1971. Detection of Australia antigen by radioimmunoassay. Proc. Nat. Acad. Sci. U.S.A. 68:1056-1060.

2. Aach, R. D., W. K., C. A. Daniels, G. S. Scott, and A. L. Notkins. 1971. Interaction of rheumatoid factor with infectious herpes simplex virus-antibody complexes. Science 172:176-177.

3. Brier, A. M., C. Wollenberg, J. Rosenthal, M. Mage, and A. L. Notkins. 1971. Inhibition or enhancement of immunologial injury of virus-infected cells. Proc. Nat. Acad. Sci. U.S.A. 68:3073-3077.

4. Cardiff, R. D., P. B. Blair, and P. Nakayama. 1967. In vitro cultivation of mouse mammary tumor virus: detection of MTV production by radioisotope labeling and identification by immune precipitation. Proc. Nat. Acad. Sci. U.S.A. 59:895-902.

5. Catt, K., and G. W. Treger. 1967. Solid-phase radioimmunoassay in antibody-coated tubes. Science 158:1570-1572.

6. Coller, J. A., I. Millman, T. C. Halbhen, and B. S. Blumberg. 1971. Radioimmunoassay for Australia antigen, antibody, and antigen-antibody complexes. Proc. Soc. Exp. Biol. Med. 138:249-257.

7. Dalrymple, J. M., A. A. Teramoto, R. D. Cardiff, and P. K. Russell. 1972. Radioimmune precipitation of group A arboviruses. J. Immunol. 109:426-433.

8. Daniels, C. A., S. E. Mergenhagen, and A. L. Notkins. 1970. Measurement of antibody against human IgG by the neutralization of IgG-sensitized herpes simplex virus. J. Immunol. 104:470-474.

9. Daugherty, H. 1971. Immunoprecipitin reaction of influenza virus-antibody complex with anti-IgG. J. Immunol. 107:392-399.

10. Daugherty, H., M. L. Davis, and H. S. Kaye. 1972. Immunoglobulin class of influenza antibodies investigated by radioimmunoassay (RIA). J. Immunol. 109:549-556.

11. Daugherty, H., D. T. Warfield, and M. L. Davis. 1972. Solid-phase radioimmunoassay of total and influenza-specific immunoglobulin G. Appl. Microbiol. 23:360-367.

12. Felsenfeld, O. N., K. Dutta, A. D. Felsenfeld, and R. B. Brannon. 1971. Radioisotope precipitation tests with 14C and 125I labeled vaccinia antigens. Proc. Soc. Exp. Biol. Med. 138:149-151.

13. Gerloff, R. K., B. H. Hayes, and L. C. McLaren. 1962. Precipitation of radiolabeled poliovirus with specific antibody and antigen. J. Immunol. 99:559-570.

14. Hamburger, B., A. L. Notkins, M. Mage, and M. A. Keehn. 1968. Heterogeneity in the properties of 7S and 19S rabbit-neutralizing antibodies to herpes simplex virus. J. Immunol. 101:586-593.

15. Hayashi, K., J. Rosenthal, and A. L. Notkins. 1972. Iodine 125-labeled antibody to viral antigens: binding to the surface of virus-infected cells. Science 176:518-519.

16. Hill, A. G. S. 1971. Diagnostic and prognostic significance of rheumatoid factor. p. 143-153. In J. J. R. Duthie and W. R. M. Alexander (ed.), Rheumatic diseases. Williams and Wilkins Co., Baltimore.

17. Hollinger, F. B., V. Vornom, and R. Dreesman. 1971. Assay of Australian antigen and antibody employing double-antibody and solid-phase radioimmunoassay techniques and comparison with the passive hemagglutination methods. J. Immunol. 107:1099-1111.

18. Hunter, W. M., and F. C. Greenwood. 1962. Preparation of iodine-131 labeled human hormone of high specific activity. Nature (London) 194:495-496.

19. Kempe, C. H., V. Fulginiti, M. Minamitani, and H. Shinfeld. 1968. Smallpox vaccine of eczema patients with a strain of attenuated live vaccinia (CVI-78). Pediatrics 42:980-985.

20. Kirkham, K. E., and W. M. Hunter. 1971. Workshop meeting on radioimmunoassay methods. Churchill Livingston, London.

21. Lander, J. J., H. J. Alter, and R. H. Purcell. 1971. Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J. Immunol. 105:1166-1170.

22. Ling, C. M., and L. R. Overy. 1972. Prevalence of hepatitis B virus antigen as revealed by direct radioimmunoassay with anti-HB-antibody. J. Immunol. 109:834-840.

23. McConahey, P. J., and F. J. Dixon. 1966. A method of trace iodination of proteins for immunologic studies. Int. Arch. Allergy 28:155-169.

24. Notkins, A. L., J. Rosenthal, and B. Johnson. 1971. Rate-zonal centrifugation of herpes simplex virus-antibody complexes. Virology 43:321-335.

25. Ozer, H. L., K. Takemoto, R. L. Kirschstein and D. Axelrod. 1969. Immunological characterization of plague mutants of simian virus 40. J. Virol. 3:17-24.

26. Rosenthal, J. D., K. Hayashi, and A. L. Notkins. 1972. Rapid microradioimmunoassay for the measurement of antiviral antibody. J. Immunol. 100:586-592.

27. Schroenblocher, R. E., H. G. Kunkel, and T. B. Tomasi. 1964. Activity of dissociated and reassociated 19S anti-y-globulins. J. Exp. Med. 120:1215-1229.

28. Walsh, J. H., R. Yalow, and S. A. Berson. 1970. Detection of Australian antigen and antibody by means of radioimmunoassay techniques. J. Infect. Dis. 121:550-554.

29. Wiktor, T. J., H. Koprowski, and F. J. Dixon. 1972. Radioimmunoassay procedure for rabies binding antibodies. J. Immunol. 109:464-470.